442 related articles for article (PubMed ID: 20684722)
1. Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa.
Pawinski R; Debrus S; Delem A; Smolenov I; Suryakiran PV; Han HH
J Infect Dis; 2010 Sep; 202 Suppl():S80-6. PubMed ID: 20684722
[TBL] [Abstract][Full Text] [Related]
2. Update on Rotarix: an oral human rotavirus vaccine.
O'Ryan M; Linhares AC
Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
[TBL] [Abstract][Full Text] [Related]
3. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
[TBL] [Abstract][Full Text] [Related]
4. Rotavirus vaccination within the South African Expanded Programme on Immunisation.
Seheri LM; Page NA; Mawela MP; Mphahlele MJ; Steele AD
Vaccine; 2012 Sep; 30 Suppl 3():C14-20. PubMed ID: 22939015
[TBL] [Abstract][Full Text] [Related]
5. Rotavirus vaccines: targeting the developing world.
Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
[TBL] [Abstract][Full Text] [Related]
6. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
Patel MM; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A44-51. PubMed ID: 22520136
[TBL] [Abstract][Full Text] [Related]
8. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Chandran A; Santosham M
Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.
Phua KB; Lim FS; Lau YL; Nelson EA; Huang LM; Quak SH; Lee BW; Teoh YL; Tang H; Boudville I; Oostvogels LC; Suryakiran PV; Smolenov IV; Han HH; Bock HL
Vaccine; 2009 Oct; 27(43):5936-41. PubMed ID: 19679216
[TBL] [Abstract][Full Text] [Related]
10. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine.
Nakagomi T; Cuevas LE; Gurgel RG; Elrokhsi SH; Belkhir YA; Abugalia M; Dove W; Montenegro FM; Correia JB; Nakagomi O; Cunliffe NA; Hart CA
Arch Virol; 2008; 153(3):591-3. PubMed ID: 18175037
[TBL] [Abstract][Full Text] [Related]
11. Rotavirus vaccine: early introduction in Latin America-risks and benefits.
Pérez-Vargas J; Isa P; López S; Arias CF
Arch Med Res; 2006 Jan; 37(1):1-10. PubMed ID: 16314179
[TBL] [Abstract][Full Text] [Related]
12. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
[TBL] [Abstract][Full Text] [Related]
13. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B
Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978
[TBL] [Abstract][Full Text] [Related]
14. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of an ideal rotavirus vaccine.
Reisinger KS; Block SL
Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
[TBL] [Abstract][Full Text] [Related]
16. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
Ciarlet M; Schödel F
Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
[TBL] [Abstract][Full Text] [Related]
17. Global impact of rotavirus vaccines.
Tate JE; Patel MM; Steele AD; Gentsch JR; Payne DC; Cortese MM; Nakagomi O; Cunliffe NA; Jiang B; Neuzil KM; de Oliveira LH; Glass RI; Parashar UD
Expert Rev Vaccines; 2010 Apr; 9(4):395-407. PubMed ID: 20370550
[TBL] [Abstract][Full Text] [Related]
18. Live attenuated human rotavirus vaccine, Rotarix.
Bernstein DI
Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369
[TBL] [Abstract][Full Text] [Related]
19. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program.
Amador JJ; Vasquez J; Orozco M; Pedreira C; Malespin O; De Oliveira LH; Tate J; Parashar U; Patel M
Int J Infect Dis; 2010 Jul; 14(7):e592-5. PubMed ID: 20022778
[TBL] [Abstract][Full Text] [Related]
20. A critical time for rotavirus vaccines: a review.
Cunliffe NA; Nakagomi O
Expert Rev Vaccines; 2005 Aug; 4(4):521-32. PubMed ID: 16117709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
